LRRK2 antibody (Glu519)

Catalog No. ABIN1882108

Product Details anti-LRRK2 Antibody

Target: LRRK2 (Leucine-Rich Repeat Kinase 2 (LRRK2))

Binding Specificity: AA 504-536, Glu519

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This LRRK2 antibody is un-conjugated

Application: Western Blotting (WB)

Purification: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS. Purified Rabbit Polyclonal Antibody (Pab)

Immunogen: This PARK8(LRRK2) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 504-536 amino acids from human PARK8(LRRK2).

Clone: RB7205

Application Details

Application Notes: WB: 1:1000

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 2 mg/mL

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Preservative: Sodium azide

Precaution of Use: WARNING: Reagents contain sodium azide. Sodium azide is very toxic if ingested or inhaled. Avoid contact with skin, eyes, or clothing. Wear eye or face protection when handling. If skin or eye contact occurs, wash with copious amounts of water. If ingested or inhaled, contact a physician immediately. Sodium azide yields toxic hydrazoic acid under acidic conditions. Dilute azide-containing compounds in running water before discarding to avoid accumulation of potentially explosive deposits in lead or copper plumbing.

References for anti-LRRK2 antibody (ABIN1882108)

Biskup, Moore, Rea, Lorenz-Deperieux, Coombes, Dawson, Dawson, West: "Dynamic and redundant regulation of LRRK2 and LRRK1 expression." in: BMC neuroscience, Vol. 8, pp. 102, (2008) (PubMed).

Shen: "Protein kinases linked to the pathogenesis of Parkinson's disease." in: Neuron, Vol. 44, Issue 4, pp. 575-7, (2004) (PubMed).

Wszolek, Pfeiffer, Tsuboi, Uitti, McComb, Stoessl, Strongosky, Zimprich, Müller-Myhsok, Farrer, Gasser, Calne, Dickson: "Autosomal dominant parkinsonism associated with variable synuclein and tau pathology." in: Neurology, Vol. 62, Issue 9, pp. 1619-22, (2004) (PubMed).

Target Details for LRRK2

Target: LRRK2 (Leucine-Rich Repeat Kinase 2 (LRRK2))

Alternative Name: PARK8 (LRRK2) (LRRK2 Products)

Synonyms: LRRK2 antibody, AURA17 antibody, DARDARIN antibody, PARK8 antibody, RIPK7 antibody, ROCO2 antibody, 4921513O20Rik antibody, 9330188B09Rik antibody, AW561911 antibody, D630001M17Rik antibody, Gm927 antibody, cI-46 antibody, leucine-rich repeat kinase 2 antibody, leucine rich repeat kinase 2 antibody, lrrk2 antibody, LRRK2 antibody, Lrrk2 antibody

Background: Parkinson is the second most common neurodegenerative disease after Alzheimers. About 1 percent of people over the age of 65 and 3 percent of people over the age of 75 are affected by the disease. The mutation is the most common cause of Parkinson's disease identified to date. LRRK2, a genetic mutation, was recently found linked to about 5 percent of inherited cases of Parkinson's disease. By high-resolution recombination mapping and candidate gene sequencing in 46 families, 6 disease-segregating mutations (5 missense and 1 putative splice site mutation). It may be central to the pathogenesis of several major neurodegenerative disorders associated with parkinsonism. LRRK2 belongs to the ROCO protein family and includes a protein kinase domain of the MAPKKK class and several other major functional domains.

Synonyms: LRRK2, PARK8, Leucine-rich repeat serine/threonine-protein kinase 2, Dardarin

NCBI Accession: NP_940980

UniProt: Q5S007

Pathways: Regulation of G-Protein Coupled Receptor Protein Signaling, Skeletal Muscle Fiber Development